Donaldson Company, Inc. — FY2023 Form 10-K Summary
Reporting period: Fiscal year ended July 31, 2023. This is an annual filing; it does not provide a standalone fiscal fourth-quarter results summary. Unless stated otherwise, figures are in millions of U.S. dollars.
Business context
Donaldson is a global filtration products and solutions company. Its three reportable segments are Mobile Solutions, Industrial Solutions and Life Sciences. Fiscal 2023 sales were distributed geographically as follows: U.S. and Canada 42.7%, EMEA 29.4%, APAC 17.7% and Latin America 10.2%. Mobile Solutions generated 63.4% of sales, Industrial Solutions 29.6% and Life Sciences 7.0%.
Key financial results
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Net sales | $3,430.8 | $3,306.6 | +3.8% |
| Gross profit / gross margin | $1,160.6 / 33.8% | $1,067.4 / 32.3% | Margin +1.5 percentage points |
| Operating income / operating margin | $480.2 / 14.0% | $443.5 / 13.4% | Income +8.3% |
| Net earnings / net margin | $358.8 / 10.5% | $332.8 / 10.1% | Earnings +7.8% |
| Diluted EPS | $2.90 | $2.66 | +9.0% |
| Cash from operating activities | $544.5 | $252.8 | +$291.7 |
| Capital expenditures | $118.5 | $85.5 | +$33.0 |
Management attributed sales growth mainly to pricing, while foreign currency translation reduced reported sales by $113.4 and net earnings by $14.4. Higher pricing and operating efficiencies helped improve gross margin; the company said prior-year inflation in raw materials, labor and energy continued to weigh on margins.
Segments and material changes
- Mobile Solutions: Sales increased 2.3% to $2,174.8; excluding currency effects, sales increased 5.7%. Segment earnings before income taxes rose 12.5% to $330.4. Off-Road growth and pricing were partly offset by aftermarket volume declines associated with large OEM customer inventory reductions.
- Industrial Solutions: Sales increased 12.6% to $1,014.7; excluding currency effects, sales increased 15.6%. Segment earnings before income taxes rose 40.0% to $186.2, supported by pricing, efficiencies and expense leverage.
- Life Sciences: Sales declined 13.5% to $241.3; excluding currency effects, sales declined 9.0%. Segment earnings before income taxes fell to $9.9 from $64.9, reflecting weak disk-drive demand and expected initial negative earnings effects from recent acquisitions, partly offset by growth in food and beverage and bioprocessing.
- Donaldson acquired Isolere and Univercells Technologies during FY2023 for $209.2 net of cash acquired. The acquired businesses’ FY2023 sales were immaterial. The company also reorganized its reporting segments, recasting historical segment information.
Cash, debt and liquidity
- Cash and cash equivalents were $187.1 at year-end, compared with $193.3 a year earlier. Operating cash flow increased substantially, primarily because inventory declined rather than increased as it had in FY2022, and because earnings were higher.
- Investing cash outflow was $327.3, including $209.2 for acquisitions and $118.5 of property, plant and equipment purchases. Financing cash outflow was $222.2, including $114.4 in dividends and $141.8 in share repurchases.
- Total debt was $655.7, compared with $648.0; long-term debt was $496.6. Debt was 33.2% of total capitalization, down from 36.4%. The company reported compliance with its debt covenants.
- Remaining borrowing capacity was $224.4 under short-term facilities and $396.3 under the revolving credit facility, or $620.7 in total. Management stated that cash, expected operating cash generation and available credit should meet liquidity needs for the next 12 months and beyond.
- Inventory declined to $418.1 from $502.4; days inventory outstanding improved to 69 from 78. Days sales outstanding increased to 64 from 62.
Outlook, risks and unusual items
- The filing gives no specific FY2024 sales, earnings or EPS guidance. It forecasts FY2024 capital expenditures of $95–$115, principally for capacity expansion, new products and technology, and infrastructure.
- Fiscal 2023 included $21.8 of organizational redesign and exit-related charges: $15.3 for severance and redesign, and $6.5 mainly related to exiting a lower-margin customer program and product.
- Backlog expected to be delivered within 90 days was $576.4 at July 31, 2023, down from $658.5 a year earlier. The company cautions that backlog is not necessarily indicative of future results.
- Principal disclosed risks include global economic and geopolitical conditions, cyclical end-market demand, foreign exchange, raw-material and supply-chain availability and costs, pricing competition, labor availability, manufacturing capacity, disruptive technologies including electrification, acquisition integration, cybersecurity, regulation and environmental compliance.
- The company guarantees half of certain debt and banking obligations of its 50%-owned AFSI joint venture; AFSI’s outstanding debt was $59.6. Management said it did not expect the guarantee to have a current or future material effect. Recorded litigation liabilities were not material, and management considered materially larger settlements remote.
- Independent auditors issued an unqualified opinion on the financial statements and internal controls; management and the auditor reported effective internal control over financial reporting as of July 31, 2023.
Important facts for investors to verify
- Whether the improved gross and operating margins persist as pricing benefits encounter input-cost, wage and energy pressures.
- Whether Life Sciences disk-drive demand recovers and the Isolere and Univercells acquisitions deliver expected growth and profitability.
- How much of the reported operating cash-flow increase came from inventory reduction, and whether working-capital improvements are sustainable.
- Debt repayment and refinancing plans for the $125.0 of debt maturing in March 2024 and the €80.0 variable-rate term loan due in October 2024.
- Actual FY2024 capital expenditures compared with the stated $95–$115 range, and any subsequent formal operating guidance.
- Progress in reducing the backlog decline and the effects of OEM inventory adjustments on aftermarket sales.